Updated Jul 16, 2026 · Last SEC filing 2026-07-15
Oruka Therapeutics, Inc. (ORKA) has filed 20 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-15. 4 Form 8-K material event filings were reported by ORKA in the last 90 days. 7 Form 144 notices of proposed sale were filed for ORKA stock. InsiderAlpha tracks every ORKA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0000907654 |
|---|
| Form 4 filings (90d) | 20 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 7 |
| Latest Form 4 filing | 2026-07-15 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Goncalves Joana | Chief Medical Officer | S — Open-market sale [10b5-1] | 2.5K | $85.86 | $214K | SEC | |
| Goncalves Joana | Chief Medical Officer | S — Open-market sale [10b5-1] | 400 | $84.36 | $34K | SEC | |
| Goncalves Joana | Chief Medical Officer | S — Open-market sale [10b5-1] | 300 | $87.25 | $26K | SEC | |
| Goncalves Joana | Chief Medical Officer | M — Option exercise [10b5-1] | 3.5K | $7.80 | $27K | SEC | |
| Goncalves Joana | Chief Medical Officer | S — Open-market sale [10b5-1] | 3.8K | $86.68 | $330K | SEC | |
| Goncalves Joana | Chief Medical Officer | M — Option exercise [10b5-1] | 3.5K | $6.84 | $24K | SEC | |
| Agarwal Arjun | Senior Vice President, Finance | S — Open-market sale [10b5-1] | 3.7K | $84.26 | $315K | SEC | |
| Agarwal Arjun | Senior Vice President, Finance | S — Open-market sale [10b5-1] | 300 | $83.07 | $25K | SEC | |
| Agarwal Arjun | Senior Vice President, Finance | S — Open-market sale [10b5-1] | 5.7K | $84.90 | $480K | SEC | |
| Agarwal Arjun | Senior Vice President, Finance | M — Option exercise [10b5-1] | 8.5K | $12.50 | $107K | SEC | |
| Agarwal Arjun | Senior Vice President, Finance | M — Option exercise [10b5-1] | 1.5K | $34.39 | $50K | SEC | |
| Agarwal Arjun | Senior Vice President, Finance | S — Open-market sale [10b5-1] | 300 | $85.63 | $26K | SEC | |
| Sandler Laura Lee | Chief Operating Officer | M — Option exercise | 5.0K | $7.80 | $39K | SEC | |
| Sandler Laura Lee | Chief Operating Officer | S — Open-market sale | 2.2K | $93.85 | $210K | SEC | |
| Fairmount Funds Management LLC | Director | S — Open-market sale | 3.55M | $84.43 | $300.01M | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Oruka Therapeutics, Inc. (ORKA). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Agarwal Arjun | 26 | $2.80M |
| Goncalves Joana | 23 | $1.74M |
| Sandler Laura Lee | 14 | $911K |
| Dambkowski Carl | 12 | $9.14M |
| Fairmount Funds Management LLC | 4 | $300.01M |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ORKA insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live ORKA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.